Profusa Shares to Reverse Split on Tuesday, July 7th (NASDAQ:PFSA)

Profusa, Inc. (NASDAQ:PFSA) shares are set to reverse split before the market opens on Tuesday, July 7th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, July 6th.

Profusa Stock Performance

Shares of PFSA remained flat at $0.09 on Friday. The company had a trading volume of 6,920,470 shares, compared to its average volume of 7,584,541. The business has a 50-day moving average price of $0.33 and a 200 day moving average price of $2.53. The firm has a market capitalization of $435,710.00, a PE ratio of -0.00 and a beta of 0.47. Profusa has a one year low of $0.08 and a one year high of $180.00.

Profusa (NASDAQ:PFSA) last issued its quarterly earnings results on Friday, May 15th. The company reported ($2.05) EPS for the quarter.

Analyst Ratings Changes

A number of analysts recently issued reports on PFSA shares. Wall Street Zen upgraded shares of Profusa from a “strong sell” rating to a “sell” rating in a report on Saturday, April 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Profusa in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.